Wall Street's top stock picks for 2026: Goldman's under-the-radar name with upside

Goldman Sachs names Houlihan Lokey (market cap ~$12bn) its top stock pick, assigning a $237 price target implying ~36% upside from the last price of $173.70 and noting a 1.37% dividend yield. Analyst James Yaro cites ~22% of trailing-12-month revenue from restructuring as protection in a downturn, strong expense discipline supporting margins, and expected bolt-on acquisitions under CEO Scott Joseph Adelson as key upside drivers.

Analysis

Market structure: Houlihan Lokey (HLI) is a direct winner from a weaker macro cycle — ~22% of trailing revenue is restructuring, which is countercyclical and should increase if high‑yield defaults and stressed credit volumes rise. Mid‑market and sponsor M&A fees (HLI’s strength) gain share versus bulge‑brackets that focus on mega‑deals, improving HLI’s pricing power on smaller mandates. Systemically, rising stressed credits would widen corporate bond and loan spreads (bearish for leveraged loan ETFs, bullish for distressed debt strategies) and lift implied vol in IB equities and puts.

Risk assessment: Tail risks include a sudden freeze in credit markets that kills deal flow (high‑probability short pain) or an acquisitive CEO overpaying for bolt‑ons, compressing ROE (high‑impact medium probability). Immediate effects (days) are headline‑driven price moves; short term (3–12 months) depends on announced bolt‑ons and quarterly restructuring fees; long term (2–5 years) hinges on integration success and whether M&A wins translate to recurring fee pools. Hidden dependency: HLI performance is levered to sponsor liquidity and leveraged‑loan market depth — monitor ICE BofA HY OAS and leveraged loan CLO issuance as second‑order signals.

Trade implications: Direct: asymmetric long in HLI sized 2–3% of equity portfolio to capture ~36% upside to Goldman’s $237 PT within 6–12 months, with a 12–15% stop‑loss. Pair trade: long HLI vs short Evercore (EVR) or other pure advisory boutiques (size 1–2%) to isolate restructuring vs pure M&A exposure. Options: implement a funded Jan‑2026 180/260 call spread to cap capital, or buy 12–18 month OTM calls if expecting quicker repricing on bolt‑on announcements.

Contrarian angles: Consensus underestimates execution risk from an M&A‑hungry CEO — bolt‑ons could dilute near‑term margins if paid with stock or high cash, so upside is conditional. Historical parallels (post‑2008 boutiques) show restructuring specialists can outperform during stressed cycles but underperform when credit recovery is rapid and fee pools contract; if HY spreads tighten by >200 bps from current levels, the trade can reverse quickly. Watch for regulatory scrutiny on fees or client conflicts if deal volume spikes; these would be catalysts for re‑rating downside.

Key Decisions for Investors

• Establish a 2–3% long equity position in HLI (ticker: HLI) within 1–4 weeks, target price $237 (Goldman TP, ~36% upside) and place a hard stop at −12% to −15% from entry; scale into size on any pullback ≥5%.
• Implement a relative‑value pair: long HLI (1–2%) vs short EVR (Evercore) or another pure M&A advisory (1–2%) for a 6–12 month trade to capture restructuring skew; unwind if HLI/EVR spread narrows <10% or if HLI announces >$200m acquisition financed >50% with equity.
• Use options to cap downside: buy a Jan‑2026 HLI 180C and sell a Jan‑2026 260C (1:1 call spread) sized to cost ≈1–2% of portfolio; target gross return ≥2.5x premium (equates to reaching Goldman TP) and exit on earnings beat or announced bolt‑on within 30 trading days after announcement.
• Reduce cyclical bank/regional exposure by 2–4% if ICE BofA US High Yield OAS widens >150 bps from current levels or if leveraged loan CLO issuance drops >30% QoQ; redeploy proceeds into distressed credit ETFs or specialist managers benefiting from higher restructuring activity.